Evaluation of serum biomarkers in nutritional disorders: Glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects

Immunopharmacology and Immunotoxicology

Volumn 30, Issue 4, 2008, Pages 925-936

  De Michele, Giampietro ^a   Correale, Mario ^a   De Michele, Onofrio ^a   Guerra, Vito ^a   Mazzarelli, Rosalba ^a   Misciagna, Giovanni ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Fructosamine; Glycated apolipoprotein B; Labile glycated hemoglobin; Serum triglycerides; Stable glycated hemoglobin

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS; FASTING; FEMALE; FOLLOW-UP STUDIES; FRUCTOSAMINE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NUTRITION DISORDERS; TRIGLYCERIDES;

EID: 54949120626     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970802337718     Document Type: Article

References (51)

1. Means, G.E.; Chang, M.K. Nonenzymatic glycosylation of proteins, structure and function changes. Diabetes 1982, (31), 1-4.
2. Vlassara, H. Recent progress in advanced glycation end products and diabetic complication. Diabetes 1997, (46), S19-S24.
3. Wang, X.; Bucala, R.; Milne, R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc. Natl. Acad. Sci. USA 1998, 95(13), 7643-7647.
4. Vlassara, H.; Bucala, R.; Striker, L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 1994 70(2), 138-151.
5. Vitek, M.P.; Bhattacharva, K.; Glendening, J.M.; Stopa E.; Vlassara, H.; Bucala, R.; Manogue, K.; Cerami, A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease.Proc. Natl. Acad. Sci. U S A 1994, 91(11), 766-770.
6. st ed. Oxford: Oxford University Press, Inc., 2000, p. 24-45.
7. Chappey, O.; Dosquet, C.; Wautier, M.P.; Wautier, J.L. Advanced glycation end products, oxidant stress and vascular lesions. Eur. J. Clin. Invest. 1997, (27), 97-108.
8. Schmidt, A.M.; Hori, O.; Brett, J.; Yan, S.D.; Wautier, J.L.; Stern, D. Cellular receptors for advanced glycation end products- implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 1994, (14), 1521-1528.
9. Perry, I.J.; Wannamethee, S.G.; Whincup, P.H.; Shaper, A.G. Asymptomatic hyperglycemia and major ischemic heart disease events in Britain. J. Epidemiol. Commun. Health 1994, (48), 538-542.
10. Aronson, D.; Johnston, M.T. Coronary artery disease in diabetes. In Johnstone MT, Veves A. Diabetes and cardiovascular disease. Human Press, Totowa, NJ-USA, 2001, pp. 247-279.
11. Misciagna, G.; De Michele, G.; Trevisan, M. Non enzymatic glycated proteins in the blood and cardiovascular disease. Curr. Pharma.Des. 2007, (13), 3688-3695.
12. La Vecchia, C.; Negri, E.; Recarli, A.; Franceschi, S. diabetes mellitus and colorectal cancer risk. Cancer Epidemiol. Biomark. Prev. 1997, (6), 1007-1010.
13. Will, J.C.; Galuska, D.A.; Vinicor, F.; Calle, E.E. Colorectal cancer: another complication of diabetes mellitus? Am. J. Epidemiol. 1998, (147), 816-825.
14. Misciagna, G.; De Michele, G.; Guerra, V.; Cisternino, A.M.; Di Leo, A.; Freudenheim, J.L.; Interosp Group. Serum fructosamine and colorectal adenomas. Eur. J. Epidemiol. 2004, (19), 425-432.
15. Larsson, S.C.; Bergkvist, L.; Wolk, A. Consumption of sugar and sugar-sweetened foods and risk of pancreatic cancer in a prospective study. Am. J. Clin. Nutr. 2006, 84(5), 1171-1176.
16. Platek, M.; Krogh, V.; Micheli, A.; Browne, R.; Meneghini, E.; Sieri, S.; Schunemann, H.J.; Pala, V.; Barba, M.; Wilding, G.E.; Berrino, F.; Muti, P. Serum fructosamine and subsequent breast cancer risk: A nested case-control study in the ORDET prospective cohort study. Cancer Epidemiol. Biomarkers Prev. 2005, 14(1), 271-274.
17. Sacks, D.B.; Bruns, D.E.; Goldstein, D.E.; Maclaren, N.K.; McDonald, J.M.; Parrott, M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem.,2002, (25), 436-472.
18. Liu, K.; Stamler, J.; Stamler, R. Methodological problems in characterizing an individual's plasma glucose level. J. Chron. Dis., 1982, (35), 475-485.
19. Timothy, J.L. Lipoprotein glycation and its metabolic consequence. Diabetes 1992, (41), 67-73.
20. 1c in evaluating the achievement of therapeutic goals in diabetes? Diab. Met. (Paris), 2001, 27, 598-603.
21. Misciagna, G.; De Michele, G.; Costernino, A.M.; Guerra, V.; Logroscino, G.; Freudenheim, J.L. Dietary carbohydrates and proteins in the blood in non diabetics subjects. J. Am.Coll. Nutr. 2005, (24), 22-29.
22. 1c. J. Clin. Inv. 1976, (57), 1652-1659.
23. Johnson, R.N.; Metcalf, P.A.; Baker, J.R. Fructosamine: a new approach to the estimation of serum control of serum glycosylprotein. An index of diabetic control. Clin. Chim. Acta 1982, (127), 87-95.
24. 1c. N. Z. Med. J. 1997, (110), 460-462.
25. Day, J.; Ingebretsen, C.G.; Ingebretsen, W.R.; Baynes, J.W.; Thorpe, S.R. Nonenzymatic glucosylation of serum proteins and hemoglobin: Response to changes in blood glucose levels in diabetic rats. Diabetes 1980, (29), 524-527.
26. Misciagna, G.; De Michele, G.; Logroscino, G.; Cisternino, A.M.; Guerra, V.; Freudenheim, J.L. Fructosamine, glycated hemoglobin, and dietary carbohydrates. Clin. Chim. Acta 2004, (340), 139-147.
27. Stahl, A.J.C.; Rima, A.; Blickle, J.F.; Brogard, J.M. Short-term variations of serum glycated apolipoprotein B. Diab. Metab. 1998, (24), 151-155.
28. Svendsen, P.A.; Christiansen, J.S.; Welinder, B.; Nerup, J. Fast glycosylation of hemoglobin. Lancet 1979, (i), 603.
29. Misciagna, G.; Logroscino, G.; De Michele, G. Guerra, V.; Cisternino, A.M.; Caruso M.G.; Trevisan M. Glycated apolipoprotein B and myocardial infraction. Nutr. Metab. Card. Dis. 2007, (17), 6-12.
30. Cohen, M.P.; Lautenslager, G.; Shea, E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur. J. Clin. Chem. Clin. Biochem. 1993, 31(11), 707-713.
31. Higgins, P.J.; Bunn, H.F. Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J. Biol. Chem. 1981, 256(10), 5205-5208.
32. Flückiger, R.; Woodtli, T.; Berger, W. Evaluation of the fructosamine test for the measurement of glycated plasma protein. Diabetologia 1987, (30), 648-652.
33. Schleicher, E.; Deufel, T.; Wieland, O.H. Non-enzymatic glycosylation of human serum lipoproteins. Elevated ε-lysine glycosylated low density lipoprotein in diabetics patients. FEBS Lett. 1981, 129(1), 1-4.
34. Kim, H.J.; Kurup, I.V. Nonenzymatic glycosylation of human plasma low density lipoproteins: Evidence for in vitro and in vivo glycosylation. Metabolism 1982, (31), 348-353.
35. Witztum, J.L.; Mahoney, E.M.; Branks, M.J.; Fisher, M.; Elam, R.; Steinberg, D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982, (31), 283-291.
36. Triau, J.E.; Arbetter, J.; Schaefer, E.J. Impaired hepatocyte binding, uptake and degradation of glucosylated low-density lipoproteins. Biochem. Biophys. Acta 1986, (877), 359-365.
37. Krämer-Guth, A.; Quaschning, T.; Galle, J.; Baumstark, M.W.; Königer, M.; Nauck, M.; Schollmeyer, P.; März, W.; Wanner, C. Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. E. J. Clin. Invest. 1997, (24), 460-468.
38. Sasaki, J.; Okamura, T.; Cottam, G.L. Measurement of receptor-independent metabolism of low-density lipoprotein: An application of glycosylated low-density lipoprotein. Eur. J. Biochem. 1983, (131), 535-538.
39. Brown, M.S.; Goldstein, J.L. Familiar hypercholesterolemia: genetic, biochemical and pathophysiologic consideration. Adv. Intern. Med. 1975, (20), 273-296.
40. Lops-Virella, M.F.; Klein, R.K.; Lyons, T.J.; Stevenson, H.C. Glycosylation of low-density lipoprotein enhances cholesterol ester synthesis in human monocyte-derived macrophages. Diabetes 1988, (37), 550-557.
41. Lyons, T.J.; Jenkins, A.J. Glycation, oxidation, and lipoxidation in the development of the complication of diabetes: A carbonyl stress hypothesis. Diab. Rev. 1997, 5(4), 365-391.
42. Feingold, K.; Grunfeld, C.; Pang, M.; Doerrler, W.; Krauss, R. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler. Thromb. 1992, (12), 1946-1952.
43. Matsui, H.; Okumura, K.; Toki, Y.; Hayakawa, T. Low-density lipoprotein particle size as an independent predictor of glycated low-density lipoprotein level. Diab.Care 1999, 33(7), 1220-1221.
44. Gillery, P.; Hue, G.; Bordas-Fonfrède, M.; Chapelle, J.P.; Druin, P.; Lévy-Marchal, C.; Périer, C.; Sélam, J.L.; Slama, G.; Thivolet, C.; Vialettes, B. Hemoglobin A1C determination and hemoglobinopathies: problems and strategies. Ann. Biol. Clin. (Paris) 2000, 58(4), 425-429.
45. 1c can be assessed with erythrocyte creatine in patients with shortened erythrocyte age. Diab. Care 1998, (21), 1732-1735.
46. Lahousen, T.; Hegenbarth, K.; Ille, R.; Lipp, R.W.; Krause, R.; Little, R.R.; Schnedl, W.J. Determination of glycated hemoglobin in patients with advanced liver disease. World J. Gastroenterol. 2004, 10(15), 2284-2286.
47. Ansari, A.; Thomas, S.; Goldsmith, D. Assessing glycemic control inpatients with diabetes and end-stage renal failure. Am. J. Kidney Dis. 2003, (41), 523-531.
48. Chujo, K.; Shima, K.; Tada, H.; Oohashi, T.; Minakuchi, J.; Kawashima, S. Indicators for blood glucose control in diabetics with end stage chronic renal disease: GHb vs. glycated albumin (GA). J. Med. Invest. 2006, (53), 223-228.
49. Costantini, C.; Simo, J.M.; Joven, J.; Campus, J. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: The influence of hypoalbuminaemia and hypergammaglobulinaemia. Ann. Clin. Biochem. 1992, 29 (Pt 4), 437-442).
50. Curtiss, L.K.; Witztum, J.L. A novel method of generating region-specific monoclonal antibodies to modified proteins: Application to the identification of human glucosylated low density lipoproteins. J. Clin. Invest. 1983, (72), 1427-1438
51. Lopes-Virella, M.F.; Klein, R.L.; Virella, G. Modification of lipoproteins in diabetes. Diab. Metab. Rev. 1996, 12(1), 69-90.